Alzheimer's diagnosis shifts toward early detection via blood biomarkers

Medical research and clinical practices are shifting toward the use of blood-based biomarkers to diagnose Alzheimer's disease significantly earlier than traditional symptom-based methods. A study published in The Lancet indicates that specific biomarkers, such as phosphorylated tau and amyloid-beta, can identify early neurological changes in middle-aged individuals before clinical symptoms manifest.

In Spain, health authorities in Andalucía and institutions like HCB Hospitales are integrating these less invasive blood tests, including the determination of p-tau217, into specialized clinical practice. These advancements aim to improve diagnostic precision, reduce costs, and allow for earlier intervention with disease-modifying treatments.

Experts emphasize that Alzheimer's begins years before a formal diagnosis, often through invisible biological changes. While genetic factors play a role in a small percentage of cases, many risk factors—including cardiovascular health, diabetes, and cognitive engagement—remain modifiable through lifestyle and preventative care.